Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 849Carcinoma, Non-Small-Cell Lung 551Neoplasms 509Prostatic Neoplasms 501Lung Neoplasms 313Colorectal Neoplasms 307Multiple Myeloma 289Neoplasm Metastasis 251Melanoma 241Ovarian Neoplasms 215Leukemia, Myeloid, Acute 209Pancreatic Neoplasms 206Squamous Cell Carcinoma of Head and Neck 173Carcinoma, Renal Cell 164Stomach Neoplasms 162Recurrence 161Carcinoma, Hepatocellular 160Lymphoma 156Brain Neoplasms 151Glioblastoma 147Uterine Cervical Neoplasms 144Head and Neck Neoplasms 141Lymphoma, Non-Hodgkin 140Triple Negative Breast Neoplasms 136Leukemia, Lymphocytic, Chronic, B-Cell 136Urinary Bladder Neoplasms 135Precursor Cell Lymphoblastic Leukemia-Lymphoma 132Colonic Neoplasms 115Hematologic Neoplasms 114Lymphoma, Follicular 112

Interventions

lorlatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer × Clear all
NCT05297890 2026-05-19

A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer

CStone Pharmaceuticals

Phase 2 Active not recruiting
70 enrolled
Thoracic

Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡